Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This study discusses the development of a turmeric-based herbal hair removal product named PASIKULA, highlighting its potential to increase the economic value of turmeric and acceptance by consumers.

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

This study describes nursing care for a patient with Type 2 Diabetes, finding that nutritional management and insulin administration improved nutritional status and controlled blood glucose levels.

This study reported that hypoglycemia is a more frequent complication in type 1 diabetes patients than in type 2, primarily due to inappropriate insulin and anti-diabetes medication dosing.

This review found potential benefits of PRP for androgenic alopecia but highlighted the need for more rigorous studies to confirm its effectiveness.

This case report from this study demonstrates the potential of treating severe alopecia areata with a combination of microneedling, minoxidil, desoximetasone, and methylprednisolone, noting initial hair regrowth after 14 days but emphasizing the need for further research to confirm long-term efficacy and safety.

This article reviews the clinical complications and increased mortality risks associated with Cushing's syndrome but does not present new clinical data; it emphasizes the need for prompt treatment to mitigate these risks.

This review discusses consensus guidelines for the use of acitretin in psoriasis, highlighting its ongoing utility in both mono and combination therapies, despite not always being recognized in treatment guidelines.

Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.

This case report described a 67-year-old man with moderate psoriasis who developed persistent generalized hypertrichosis after 4 months of treatment with secukinumab.

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

This clinical trial found that topical rosuvastatin and melatonin creams significantly reduced the severity of mild to moderate plaque psoriasis over 12 weeks, with a satisfactory safety profile.

In this study, black cumin oil-based nanostructured lipid carriers enhanced the delivery and effectiveness of fluticasone for psoriasis in a mouse model, improving skin targeting, inflammation reduction, and permeability compared to standard cream.

This case report describes a 33-year-old male with treatment-resistant psoriasis who experienced complete resolution of symptoms and hair regrowth after following an integrated Shodhana-Shamana chikitsa regimen, with no relapse noted at follow-up, suggesting its potential for sustainable Ekakustha management.

This case report observed that an integrated Shodhana-Shamana treatment protocol effectively managed treatment-resistant Ekakustha (plaque psoriasis), resulting in complete symptom resolution and no relapse at follow-up.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

This study found that CGF may be effective in reducing inflammation and improving skin conditions in psoriasis, particularly in patients resistant to other treatments.

In this case report, a 47-year-old man with extensive psoriasis saw significant improvement in scaling and itching after using a new lotion containing clobetasol and other ingredients for one week, but further research is needed to confirm these findings.

In this study, researchers found that patients with psoriasis had a higher probability of achieving and maintaining a clinical response using brodalumab compared to ustekinumab over 52 weeks, as measured by a multistate modelling approach based on absolute PASI scores.

This study suggests that blood microarray biomarkers may help predict individual treatment response in psoriasis patients, highlighting a distinct blood signature related to inflammation, interferon, and myeloid lineage transcripts.

This study found that nonobese women with idiopathic hirsutism exhibited lower nitrite/nitrate concentrations and higher fibrinogen levels compared to control subjects, but these were similar to levels in women with polycystic ovary syndrome.

This study documented a case where Ayurvedic treatments for plaque psoriasis significantly reduced the severity of symptoms, as measured by an 84% improvement in the Psoriasis Area and Severity Index score from 6.5 to 1.04.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

In this case study, a 61-year-old male with chronic plaque psoriasis showed marked improvement in symptoms and quality of life after undergoing sodhana therapy and Bakuchi rasayana treatment, with a reduction in PASI score from 14.5 to 4.8 reported by the researchers.

In this retrospective case series, baricitinib showed effectiveness in treating severe alopecia areata but had mixed results for psoriasis and was not optimal for psoriatic arthritis in patients with coexisting conditions, suggesting further studies are needed.

This study reports that CD200R expression is significantly reduced in a mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.